News and trends on diagnostics testing, insurance coverage, and reimbursement.
Once these coverage decisions are fully implemented, 90 percent of breast cancer patients will have coverage for EndoPredict, Myriad estimated.
The program, called Genetic Testing Solution, went into effect July 1 among Anthem Blue Cross' fully-insured and self-insured members.
Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
Starting Oct. 1, the insurer will require clinicians and labs who order genetic and molecular tests for their patients to first get approval.
